0 items USD 0.00Search
Your search for "qyresearch china adalimumab industry report 2015" gave back 763240 results.
The global Adalimumab Biosimilars market size is expected to reach $ 31050 million by 2029, rising at a market growth of 3.8% CAGR during the...
Catalog:
GIR
December 2023
Price: USD 4,480.00
Biosimilar is a biologic medical product which is highly similar to another already approved biological medicine. The global Adalimumab, Infliximab...
Catalog:
MRRPB5
February 2024
Price: USD 2,900.00
The global Adalimumab Biosimilars market size was valued at US$ 22690 million in 2022. With growing demand in downstream market, the Adalimumab...
Catalog:
LPI
December 2023
Price: USD 3,660.00
Adalimumab, sold under the brand name Humira, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis,...
Catalog:
MRRPB5
April 2024
Price: USD 2,900.00
The global Adalimumab Biosimilars market size was valued at USD 23870 million in 2022 and is forecast to a readjusted size of USD 31050 million by...
Catalog:
GIR
December 2023
Price: USD 3,480.00
Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing...
Catalog:
MRRPB5
August 2023
Price: USD 4,900.00
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation. The global...
Catalog:
MRRPB5
June 2023
Price: USD 2,900.00
The global Adalimumab Monoclonal Antibody Biosimilar market size is expected to reach $ 955.4 million by 2029, rising at a market growth of 12.0%...
Catalog:
GIR
June 2023
Price: USD 4,480.00
The global Adalimumab Injection market size is expected to reach $ 2698.8 million by 2029, rising at a market growth of 5.4% CAGR during the forecast...
Catalog:
GIR
May 2023
Price: USD 4,480.00
The global Adalimumab (Humira) and Biosimilar market size is expected to reach $ 16210 million by 2029, rising at a market growth of -4.9% CAGR...
Catalog:
GIR
June 2023
Price: USD 4,480.00
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation. The global...
Catalog:
MRRPB5
June 2023
Price: USD 2,900.00
Biosimilar is a biologic medical product which is highly similar to another already approved biological medicine. The global Adalimumab, Infliximab...
Catalog:
MRRPB5
June 2023
Price: USD 4,900.00
The global Adalimumab Injection market was valued at US$ 1820 million in 2022 and is anticipated to reach US$ 2648.6 million by 2029, witnessing a...
Catalog:
MRRPB5
May 2023
Price: USD 2,900.00
The global Adalimumab Injection market size is projected to grow from US$ 1780.4 million in 2022 to US$ 2643.5 million in 2029; it is expected to...
Catalog:
LPI
May 2023
Price: USD 3,660.00
The global Adalimumab (Humira) and Biosimilar market size is projected to grow from US$ 21930 million in 2022 to US$ 14950 million in 2029; it is...
Catalog:
LPI
June 2023
Price: USD 3,660.00
